Vitamin D Supplementation on Cardiovascular Risk Factors
Maneno muhimu
Kikemikali
Maelezo
Insufficient vitamin D levels have been found in subjects with type 2 diabetes (T2D). Similarly, a negative association between serum vitamin D levels and insulin resistance has been reported in a large sample representative of the adult US population and in subjects at risk for T2D. In addition, a strong association between hypovitaminosis D and hypertriglyceridemia has been demonstrated in studies done in US adult population.
Literature has indicated that subjects with T2D and insulin resistance (IR) are more likely to develop arteriosclerosis and all of the complications related to this condition, such as myocardial infarction and stroke.
These findings have increased the interest about the effect of vitamin D on metabolic abnormalities grouped under the term "cardiovascular disease (CVD) risk factors", which includes hypertension, dyslipidemia, obesity, glucose intolerance, inflammation and T2D which is in itself a risk factor for CVD.
Therefore, the purpose of the present pilot study will be to determine the effect of supplemental vitamin D intake (4000 IU or 6000 IU of Cholecalciferol daily for 6 months) on CVD risk markers and glycemic control; primarily lipid panel, insulin resistance, and glycosylated hemoglobin (A1C), in a sample of Hispanics and African-Americans with T2D and vitamin D insufficiency. If repletion of vitamin D level improves insulin resistance, glycemic control, inflammation, hypertension, dyslipidaemia or kidney functions, it may prevent the development of CVD events and decrease T2D complications.
Tarehe
| Imethibitishwa Mwisho: | 09/30/2017 |
| Iliyowasilishwa Kwanza: | 08/06/2011 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 08/07/2011 |
| Iliyotumwa Kwanza: | 08/08/2011 |
| Sasisho la Mwisho Liliwasilishwa: | 11/12/2017 |
| Sasisho la Mwisho Lilichapishwa: | 12/11/2017 |
| Tarehe ya matokeo ya kwanza yaliyowasilishwa: | 08/04/2017 |
| Tarehe ya matokeo ya kwanza ya QC yaliyowasilishwa: | 11/12/2017 |
| Tarehe ya matokeo ya kwanza kuchapishwa: | 12/11/2017 |
| Tarehe halisi ya kuanza kwa masomo: | 06/30/2011 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 08/31/2013 |
| Tarehe ya Kukamilisha Utafiti: | 08/31/2013 |
Hali au ugonjwa
Uingiliaji / matibabu
Drug: Cholecalciferol
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Experimental: 4000 IU group This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months. | |
| Experimental: 6000 IU group This group will be given 6000 IU vitamin D3 once daily, orally for 6 months. |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 30 Years Kwa 30 Years |
| Jinsia Inastahiki Kujifunza | All |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - Type 2 diabetes - African American or Hispanic - able to ambulate on their own - aged between 30 - 70 years Exclusion Criteria: - Taking Supplemental Vitamin D - Pregnant or Lactating women - Receiving insulin therapy - Not participating in other drug trials - HIV/ hepatitis/ cancer/ liver disease/ heart failure/ any recent surgery/ mental illness/ epilepsy/ any GI or malabsorption disorders - Kidney failure or on dialysis |
Matokeo
Hatua za Matokeo ya Msingi
1. Blood Lipid [Baseline]
Hatua za Matokeo ya Sekondari
1. Glycemic Control [Baseline]
